Skip to main content

Bafiertam Side Effects

Generic name: monomethyl fumarate

Medically reviewed by Drugs.com. Last updated on Oct 12, 2023.

Note: This document contains side effect information about monomethyl fumarate. Some dosage forms listed on this page may not apply to the brand name Bafiertam.

Applies to monomethyl fumarate: oral capsule delayed release.

Serious side effects of Bafiertam

Along with its needed effects, monomethyl fumarate (the active ingredient contained in Bafiertam) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking monomethyl fumarate:

Less common

Incidence not known

Other side effects of Bafiertam

Some side effects of monomethyl fumarate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to monomethyl fumarate: oral delayed release capsule.

Hematologic

Common (1% to 10%): Lymphopenia[Ref]

Hypersensitivity

Frequency not reported: Anaphylaxis, angioedema[Ref]

Immunologic

Frequency not reported: Herpes zoster, disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, herpes zoster meningomyelitis, herpes simplex virus, West Nile virus, cytomegalovirus, Candida, Aspergillus, Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis)[Ref]

Genitourinary

Common (1% to 10%): Albumin urine present[Ref]

Hepatic

Common (1% to 10%): Aspartate aminotransferase increased

Frequency not reported: Liver injury[Ref]

Nervous system

Frequency not reported: Progressive Multifocal Leukoencephalopathy (PML)[Ref]

Cardiovascular

Very common (10% or more): Flushing (40%)[Ref]

Dermatologic

Common (1% to 10%): Pruritus, rash, erythema[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (18%), diarrhea (14%), nausea (12%)

Common (1% to 10%): Vomiting, dyspepsia[Ref]

Frequently asked questions

References

1. Product Information. Retevmo (selpercatinib). Lilly, Eli and Company. 2020.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.